OptimizeRx Corporation
OPRX
$12.41
-$0.09-0.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 94.37M | 92.13M | 88.18M | 83.20M | 78.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 94.37M | 92.13M | 88.18M | 83.20M | 78.21M |
| Cost of Revenue | 33.85M | 32.75M | 32.98M | 31.65M | 30.54M |
| Gross Profit | 60.52M | 59.38M | 55.20M | 51.55M | 47.67M |
| SG&A Expenses | 59.46M | 61.27M | 58.56M | 58.02M | 55.85M |
| Depreciation & Amortization | 4.36M | 4.33M | 4.24M | 3.61M | 3.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.67M | 98.34M | 95.78M | 93.29M | 89.39M |
| Operating Income | -3.30M | -6.22M | -7.60M | -10.08M | -11.18M |
| Income Before Tax | -16.11M | -19.38M | -33.33M | -26.26M | -25.29M |
| Income Tax Expenses | -704.00K | 725.00K | -9.16M | -8.34M | -7.22M |
| Earnings from Continuing Operations | -15.41 | -20.11 | -24.17 | -17.91 | -18.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.41M | -20.11M | -24.17M | -17.91M | -18.07M |
| EBIT | -3.30M | -6.22M | -7.60M | -10.08M | -11.18M |
| EBITDA | 1.02M | -1.89M | -3.57M | -6.58M | -8.23M |
| EPS Basic | -0.84 | -1.10 | -1.33 | -1.00 | -1.03 |
| Normalized Basic EPS | -0.29 | -0.41 | -0.43 | -0.46 | -0.44 |
| EPS Diluted | -0.84 | -1.10 | -1.34 | -1.01 | -1.04 |
| Normalized Diluted EPS | -0.29 | -0.41 | -0.43 | -0.46 | -0.44 |
| Average Basic Shares Outstanding | 73.47M | 73.17M | 72.53M | 70.84M | 69.58M |
| Average Diluted Shares Outstanding | 73.47M | 73.17M | 72.53M | 70.84M | 69.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |